Kymera Therapeutics, Inc. · NASDAQ:KYMR
Kymera Therapeutics — EADV Congress 2025
16 slides from Kymera Therapeutics's conference presentation, Sep 17, 2025
Slide 1: KT-621, an Oral, Once Daily, Targeted STAT6 Degrader: First-in-Human Phase 1a
17 September 2025 KT-621, an Oral, Once Daily, Targeted STAT6 Degrader: First-in-Human Phase 1a Safety, Pharmacokinetics, Pharmacodynamics and Th2 Biomarker Effects Mahta Mortezavi, MD Senior Medical Director, Clinical Development Kymera Therapeutics, Inc. EADV Congress | Paris | 17-20 September 202
Slide 2: Conflict of Interest Disclosure
Conflict of Interest Disclosure Arsalan Shabbir, Sagar Agarwal, Alice A. McDonald, Kelvin Shi, Annie L. Conery, Mahta Mortezavi, Nello Mainolfi, Jared Gollob, and Chad Nivens are employees with shares and stock options of Kymera Therapeutics, Inc. 2
Slide 3: Pioneering Targeted Protein Degradation for New Oral Medicines
Pioneering Targeted Protein Degradation for New Oral Medicines Targeted protein degradation (TPD) harnesses the natural cellular homeostasis and protein degradation system used to clear out misfolded or accumulated proteins to degrade disease causing proteins 1 Catching 2 Presenting Heterobifunction
Slide 4: Small Molecule Oral Degraders Can Transform Drug Development
Small Molecule Oral Degraders Can Transform Drug Development Oral Degraders Allow for Continuous, TPD Allows Drugging of Previously Undrugged Targets Complete Pathway Blockade 100 Small Pathway Signaling Traditional Small Molecule Molecule Inhibitor RNAi 80% of disease- Oral causing proteins 0 Degra
Slide 5: STAT6 Transcription Factor, Highly Validated but Undrugged Target
STAT6 Transcription Factor, Highly Validated but Undrugged Target STAT6 TRANSCRIPTION • Signal transducer and activator of transcription 6 FACTOR (STAT6) is an essential transcription factor in the interleukin (IL)-4 and IL-13 pathway Dupilumab IL-4 Dupilumab IL-4 IL-13 • IL-4/IL-13 pathway is clini
Slide 6: First STAT6-targeted Drug in Clinical Development: Preclinical Package
KT-621: First STAT6-targeted Drug in Clinical Development Compelling KT-621 Preclinical Package Provides Potential for Dupilumab-like Activity in a Pill Robust Degradation Exquisite Selectivity Full Inhibition of IL-4/IL-13 Pathways, More Potent than Dupilumab in Relevant Cell Types STAT6 Degradatio
Slide 7: First-in-Human, Phase 1a Healthy Volunteer Study
KT-621: First-in-Human, Phase 1a Healthy Volunteer Study Randomized, Double-blind, Placebo-controlled, Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) 118 Healthy Volunteers Were Endpoints Enrolled in Parts A and B Part A Part B Primary Single Ascending Dose Multiple Ascending Dose (MAD)
Slide 8: Favorable PK Profile After Single and Multiple Dosing
KT-621: Favorable PK Profile After Single and Multiple Dosing Single Dose PK Profiles Steady-State (Day 14) KT-621 Plasma Concentration (ng/mL) KT-621 Plasma Concentration (ng/mL) 6.25 mg SD n=6 Multi-Dose PK Profiles 1.5 mg QD n=9 25 mg SD n=6 12.5 mg QD n=7 75 mg SD n=6 25 mg QD n=9 200 mg SD n=6
Slide 9: Single Doses of KT-621 Achieved Rapid, Deep and Prolonged STAT6 Degradation in Blood
Single Doses of KT-621 Achieved Rapid, Deep and Prolonged STAT6 Degradation in Blood Mean Percent Change from Baseline in STAT61 100 Placebo n=12 Change from Baseline in STAT6 6.25 mg SD n=6 25 mg SD n=6 50 • Maximal degradation seen as Mean (±SE) Percent 75 mg SD n=6 200 mg SD n=6 quickly as 4 hour
Slide 10: Daily Doses Rapidly Achieve Complete STAT6 Degradation in Blood
KT-621: Daily Doses Over 14 Days Rapidly Achieve Complete STAT6 Degradation in Blood STAT6 Degradation in Blood with 14-Day Placebo n=18 12.5 mg QD n=7 50 mg QD n=9 200 mg QD n=9 KT-621 Dosing 1.5 mg QD n=9 25 mg QD n=9 100 mg QD n=9 STAT6 % Change from Baseline 100 200 STAT6 % Change from Baseline
Slide 11: Daily Doses Rapidly Achieve Complete STAT6 Degradation in Skin
KT-621: Daily Doses Over 14 Days Rapidly Achieve Complete STAT6 Degradation in Skin STAT6 Degradation in Skin with 14-Day Placebo n=17 12.5 mg QD n=7 50 mg QD n=9 200 mg QD n=9 KT-621 Dosing 1.5 mg QD n=7 25 mg QD n=8 100 mg QD n=9 STAT6 % Change from Baseline 100 STAT6 % Change from Baseline Placeb
Slide 12: Daily Doses Achieved Median TARC Reduction of Up to 37%
KT-621: Daily Doses Over 14 Days Achieved Median TARC Reduction of Up to 37% Serum TARC1 with 14-Day Thymus and Activation- KT-621 Dosing regulated Chemokine (TARC) Placebo n=18 1.5 mg QD n=9 Day 14 [CCL17] TARC % Change from Baseline 20 12.5 mg QD n=7 TARC Arm (% Change From 25 mg QD n=8 Baseline 5
Slide 13: Daily Doses Achieved Median Eotaxin-3 Reduction of Up to 63%
KT-621: Daily Doses Over 14 Days Achieved Median Eotaxin-3 Reduction of Up to 63% Serum Eotaxin-31 with 14-Day KT-621 Dosing Eotaxin-3 (CCL26) Placebo n=18 Eotaxin-3 % Change from Baseline 20 1.5 mg QD n=9 Day 14 12.5 mg QD n=7 Eotaxin-3 Arm (% Change 25 mg QD n=8 0 From Baseline 50 mg QD n=8 Median
Slide 14: Safety Summary
KT-621: Safety Summary Well Tolerated Across All Doses Evaluated and Safety Profile Undifferentiated from Placebo • No Serious Adverse Events TRAEs by Preferred Term: SAD Cohorts • No Severe Adverse Events SAD SAD AE Term (severity) Placebo KT-621 • No dose dependent pattern in (n=12) (n=36) Treatme
Slide 15: First Clinical Proof of Concept for STAT6-targeted Drug
KT-621: First Clinical Proof of Concept for STAT6-targeted Drug • Well-tolerated across all dose levels with safety profile undifferentiated from placebo. • Favorable PK profile after single and multiple daily doses, with rapid absorption after oral dosing and dose-proportional increase in exposure.
Slide 16: Thank You
Thank You For more information, please visit our Booth #B14 or www.kymeratx.com EADV Congress Paris | 17-20 September 2025 KYMERA THERAPEUTICS 500 North Beacon Street, 4th Floor Watertown, MA 02472